Both pharmacological and genetic strategies validate that targeted‐blocking the MUC1–PP2A axis significantly elevates PKCζ activity and phosphorylation of NUMB, ultimately suppressing CSLCs and tumor growth in vitro and in vivo. Here, PTPA is linked to neoplasm.